SLC5A2 and type 2 diabetes mellitus: One clinical study investigating the effects of triple therapy with SGLT-2 inhibitors, DPP-4 inhibitors, and metformin in patients with T2DM demonstrated that the addition of saxagliptin and dapagliflozin obviously improved metformin-uncontrolled HbA1c [128].